NCT05739435 is a Phase 2 clinical trial of envudeucitinib in Plaque Psoriasis, sponsored by Alumis Inc.

Who is sponsoring NCT05739435?

NCT05739435 is sponsored by Alumis Inc.

What drugs are being tested in NCT05739435?

Interventions in NCT05739435: envudeucitinib.

What condition does NCT05739435 study?

NCT05739435 studies Plaque Psoriasis.

Is NCT05739435 still recruiting?

NCT05739435 is currently active, enrolled. Last updated 1 April 2026.

Last reviewed 2026-04-01 · How we verify

NCT05739435

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis

Active, enrolled Phase 2 Last updated 1 April 2026

What this trial tests

Phase 2 trial testing envudeucitinib in Plaque Psoriasis in 165 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

17 January 2023

Primary endpoint
1 December 2026

30 December 2026

Quick facts

Lead sponsor	Alumis Inc
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	165
Start date	17 January 2023
Primary completion	1 December 2026
Estimated completion	30 December 2026
Sites	38 locations across Canada, United States

Drugs / interventions tested

envudeucitinib — full drug profile →

Conditions studied

Plaque Psoriasis — all drugs for Plaque Psoriasis →

Sponsor

Alumis Inc — full company profile →

Who can join

18 and older, any sex, with Plaque Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Allosteric TYK2 inhibition: redefining autoimmune disease therapy beyond JAK1-3 inhibitors.
Jensen LT, Attfield KE, Feldmann M, Fugger L. · · 2023 · cited 45× · PMID 37863021 · DOI 10.1016/j.ebiom.2023.104840
Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents.
Drakos A, Torres T, Vender R. · · 2024 · cited 21× · PMID 38258121 · DOI 10.3390/pharmaceutics16010111
Safety and efficacy of envudeucitinib, a highly selective, oral allosteric TYK2 inhibitor, in patients with moderate-to-severe plaque psoriasis: Results from the 52-week open-label extension period of the phase 2 STRIDE study.
Papp KA, Jacobs S, Sofen H, Bukhalo M, et al · · 2026 · cited 1× · PMID 41061968 · DOI 10.1016/j.jaad.2025.10.005

Verify or expand the search:

Other recruiting trials for Plaque Psoriasis

Currently open trials in the same condition.

NCT07357831 — A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psor · Phase 3 · recruiting
NCT07250802 — A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis · Phase 3 · recruiting
NCT06979453 — A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants Wit · Phase 3 · recruiting
NCT07234591 — A Study to Evaluate Effectiveness and Safety of a TYK2 Inhibitor in Subjects With Moderate to Severe Plaque Psoriasis · NA · recruiting
NCT07116967 — Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) · Phase 3 · recruiting

Other Alumis Inc trials

Trials by the same sponsor.

NCT06962774 — An Investigational Study of ESK-001 in Participants With Normal Renal Function and Participants With Mild, Moderate, and · Phase 1 · completed
NCT06588738 — A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 · Phase 3 · completed
NCT06586112 — A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis · Phase 3 · completed
NCT07378579 — An Investigational Study to Evaluate the Cardiac Safety Assessment (TQTc Study) of ESK-001 · Phase 1 · completed
NCT07442149 — An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05739435 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alumis Inc
Last refreshed: 1 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05739435.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing